Breast cancer survival rates have improved considerably in the last few decades in Colombia, but factors that increase the likelihood of patients experiencing cardiovascular side effects, like cardiotoxicity, are not well-known or well-treated. A recent study in the North-East region of Colombia found 11.94% of patients with a high BMI being treated for breast cancer at a regional center experienced heart damage, or cardiotoxicity, during chemotherapy. The study will be presented at the American College of Cardiology (ACC) Latin America 2023 Together with Asociación Costarricense de Cardiología in San Jose, Costa Rica.
“Cardiotoxicity is a relatively recent concern in cancer care, and its recognition as a significant issue is still evolving. In regions with limited research infrastructure and resources, there may be a lack of specific studies or initiatives addressing cardiotoxicity in the context of breast cancer treatment,” said the study’s lead author Ivetteh Gaibor Santos, MD, an internal medicine specialist at Universidad Autónoma de Bucaramanga/Fundación Oftalmológica de Santander-Foscal in Bucaramanga, Colombia, and a cardiology fellow-in-training at Fundación Universitaria de Ciencias de la Salud/Hospital de San José in Bogotá, Colombia.
An anonymized database of breast cancer patients who started chemotherapy with doxorubicin or trastuzumab between January and December 2021 was used for the study. The analysis only included patients who had a baseline echocardiogram and at least one follow-up echocardiogram. The database also recorded sociodemographic, oncological, cardiovascular and echocardiographic variables.
Cardiotoxicity was defined as a decrease in left ventricular ejection fraction (LVEF) of more than 10% reaching a value below 50% or a relative reduction of more than 15% in global longitudinal strain in patients with a normal LVEF. Ejection fraction is the amount of blood the heart pumps out each time it beats. A normal ejections fraction is 50% or higher.
The study cohort included 67 patients, with an average age of 55 years old and mean body mass index (BMI) of 26.18 kg/m². BMI is derived from the mass and height of a person. Baseline characteristics of the study cohort included obesity (20.9%), hypertension (14.93%) and Type 2 diabetes (13.43%). All of the patients had a normal LVEF before starting chemotherapy.
Results found the prevalence of cardiotoxicity was 11.94%. A body mass index of 25 and above (overweight/obesity) was the only predisposing risk factor for developing this adverse effect.
“Obesity is itself a risk factor for the development of breast cancer and cardiovascular disease like heart failure but it isn´t often properly managed, unlike other prevalent risk factors like high blood pressure,” said Gaibor Santos, who added that all patients in this study were taking antihypertensive drugs. Chemotherapeutic agents, which are formulated according to body surface area instead of body composition, may lead to further risk of cardiotoxicity in patients with obesity due to over- or under-dosing, she said.
According to the study authors, early diagnosis of cardiotoxicity and related factors is vital to allow treating clinicians to reduce adverse outcomes.
To raise awareness about the risks of cardiotoxicity in cancer treatment among health care professionals and the general population, the researchers suggest several actions, including:
- Enhanced medical education on cardiotoxicity in both medical schools and continuing medical education
- Multidisciplinary collaboration among specialties to improve the understanding of cardiotoxicity among clinicians and patients and facilitate early detection and intervention
- Encourage and support research initiatives focused on cardiotoxicity in cancer treatment
- Use of digital resources to provide clinicians with easy access to up-to-date information on cardiotoxicity
“Addressing obesity in cancer patients before starting chemotherapy as well as considering the potential risk for cardiotoxicity requires a comprehensive approach,” Gaibor Santos said. “Some strategies clinicians can consider include pre-treatment assessment, lifestyle interventions and cardiovascular risk management. It is important to note that these strategies should be tailored to each patient’s specific needs and in accordance with current evidence-based guidelines.”
“I am convinced that this is the first of many investigations that will come in the future regarding cardio-oncology in Colombia, and I am thrilled to continue working on this field because I know there are so many patients that could be benefited from the results of our upcoming studies,” Gaibor Santos said.
Learn more about ACC Latin America 2023 Together with Asociación Costarricense de Cardiología at ACC.org/LatinAmerica2023. To receive media credentials, please reach out to Katie Glenn with the ACC Press Office at kglenn@acc.org.
American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org or follow @ACCinTouch.
###